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Abstract
In the United States, renal cell carcinoma (RCC) has rapidly increased in inci-
dence for over two decades. The most common histologic subtypes of RCC,
clear cell, papillary, and chromophobe have distinct genetic and clinical charac-
teristics; however, epidemiologic features of these subtypes have not been well
characterized, particularly regarding any associations between race, disease sub-
types, and recent incidence trends. Using data from the Surveillance, Epidemi-
ology, and End Results (SEER) Program, we examined differences in the age-
adjusted incidence rates and trends of RCC subtypes, including analysis focus-
ing on racial differences. Incidence rates increased over time (2001–2009) for
all three subtypes. However, the proportion of white cases with clear cell histol-
ogy was higher than among blacks (50% vs. 31%, respectively), whereas black
cases were more likely than white cases to have papillary RCC (23% vs. 9%,
respectively). Moreover, papillary RCC incidence increased more rapidly for
blacks than whites (P < 0.01) over this period. We also observed that increased
incidence of papillary histology among blacks is not limited to the smallest size
strata. We observed racial differences in proportionate incidence of RCC sub-
types, which appear to be increasing over time; this novel finding motivates
further etiologic, clinical, molecular, and genetic studies.
Introduction
Renal cell carcinoma (RCC) comprises several distinct his-
tological subtypes, the most commonly diagnosed includ-
ing clear cell, papillary, and chromophobe. These subtypes,
classically defined by histology [1], are associated with dis-
tinct molecular and genetic characteristics [2–4]. Notably,
clear cell RCC is associated with cytogenetic loss of chro-
mosome 3p, encompassing four of the most commonly
mutated genes in this cancer: the closely linked Von Hip-
pel–Lindau (VHL) tumor suppressor gene which has been
identified to be inactivated in up to 92% of cases [5], and
the more recently recognized high-frequency mutations in
PBRM1 (polybromo 1), BAP1 [BRCA1 associated protein-
1 (ubiquitin carboxy-terminal hydrolase)], and SETD2
(SET domain containing 2) [6–8]. In contrast, neither
papillary nor chromophobe histology tumors have been
associated with any of these genomic alterations. Further,
the cytogenetic profile is highly distinct with papillary
tumors displaying trisomy 7 and 17, and chromophobe
RCC associated with multiple monosomies (characterized
by collective losses of chromosomes 1, 2, 6, 10, 13, 17, and
21) [9]. Not surprisingly, then, these tumors display differ-
ences in clinical manifestations, rates for recurrence, and
response to targeted therapy [10–14].
Several risk factors for RCC have been consistently iden-
tified in epidemiologic studies. The better established fac-
tors include cigarette smoking, body weight, hypertension,
and familial cancer syndromes [15]. Cigarette smoking has
been associated with a dose–response pattern of 20–30%
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increased risk and decrease in risk with cessation [16].
Obesity has been associated with a 40% or greater elevated
risk of RCC in U.S. studies [17, 18]. A systematic review of
BMI and cancer risk found a 24% increase in the risk of
RCC for every 5 kg/m2 increase in BMI (34% for women)
[19]. Hypertension has also been shown to be associated, in
a dose–response manner, with an increased risk of RCC
[17, 20, 21]. Although associations have been noted, an
independent effect of antihypertensive medications has not
been reported [22]. Other factors suggested to influence the
risk of RCC include diabetes, fruit, and vegetable intake,
end-stage renal disease, parity, physical activity, alcohol
consumption, and trichloroethylene exposure [15]. Most of
these associations have been reported from studies of per-
sons of European ancestry, although a few studies have sug-
gested differences in the patterns of association for several
risk factors, with higher risks found among blacks [23–25].
A recent analysis of data from two U.S. RCC case–control
studies showed that the association with obesity may vary
by histologic subtype [26]. However, there is limited evalu-
ation, using national data, of the patterns of incidence of
RCC subtypes, including secular trends. Such differences, if
found, could reveal important subtype-specific etiological
factors and identify novel targets for intervention [26, 27].
Overall RCC incidence and mortality rates have previ-
ously been reported to be similar between blacks and whites,
however, recent reports by Lipworth et al. [28]. and Chow
et al. [29]. using Surveillance, Epidemiology, and End
Results (SEER) Program data reported that both incidence
and mortality rates were significantly higher in blacks.
Moreover, incidence rates for RCC in general for African-
Americans have been rising more rapidly than whites since
the 1990s [29, 30]. A small (n = 204 total, 117 black) multi-
institutional study suggested that blacks had a significantly
higher occurrence of papillary RCC [31], a novel observa-
tion confirmed in a recent study using SEER data, which
also suggested poorer relative survival for blacks across mul-
tiple subgroups [29]. A better understanding of the contri-
bution of race to the incidence of RCC subtypes would shed
light on potentially both genetic and environmental features
that favor the development of these cancers. To explore
RCC subtype incidence patterns over the last decade, and to
examine the contribution of demographic factors, including
race, on RCC subtype incidence, we examined incidence
data from over 50,000 reported cases from across the U.S.
over the last 9 years from the 18 registries in the SEER
Program. Our analysis updates and expands a previous
analysis of SEER data presented in abstract form [32].
Material and Methods
We used data from 18 population-based registries of the
SEER Program (November 2011 release) including: Alaska
Native Tumor Registry, Atlanta, Connecticut, Detroit,
Greater California, Greater Georgia, Hawaii, Iowa, Ken-
tucky, Los Angeles, Louisiana, San Francisco-Oakland,
San Jose-Monterey, Seattle-Puget Sound, New Jersey, New
Mexico, Rural Georgia, and Utah [33].
We used the International Classification of Diseases for
Oncology, Third Edition (ICD-O-3) site code C64.9 to
identify patients with RCC diagnosed from 2001 to 2009.
We focused on the three most common histologic
subtypes, identified using the following ICD-O-3 histo-
logic codes: 8310 for clear cell, 8260 for papillary, 8317
and 8270 for chromophobe. The accuracy of the subtype
data entered for the SEER Program was recently exam-
ined in a cohort of 498 cases, and demonstrated a strong
correlation with expert pathologic review [34]. ICD-O-3
code 8312 (RCC not otherwise specified, NOS) was iden-
tified for 31,331 patients. Because of the uncertainty of
the classification of these cases over time, for this report,
we have excluded the RCC NOS cases from our primary
analysis; however, we did perform a secondary sensitivity
analysis to examine the impact of this large group of
cases. Because SEER data do not capture subtype-specific
classifications, such as papillary type 1, and papillary type
2, these additional levels of stratification were not exam-
ined for any of the three primary subtypes. The final
cohort included a total of 52,924 patients with clear cell,
papillary, and chromophobe RCC. We conducted descrip-
tive and comparative analyses of the overall incidence
among cases with the three histologic subtypes by age,
sex, and race and then examined the unadjusted odds
ratios of papillary and chromophobe subtypes in compar-
ison to clear cell. We also computed age-adjusted inci-
dence rates (cases per 100,000) standardized by Census
2000 population and tested differences in rates between
the race groups, using the method of Carriere and Roos
[35]. This is a nonparametric method which computes a
T2 statistic which follows a chi-square distribution with
large sample, but does assume the data originate from a
known distribution. This method can test the absolute
difference between two incidence estimates from two race
groups at the same time point.
We also conducted trends analysis using the Joinpoint
Regression Program (version 4.0.1, NCI) [36] to examine
differences in changes of incidence rates between race
groups by histologic type. To do this we input the
age-adjusted incidence rates in each year from 2001 to
2009 separately for whites and blacks and for each histo-
logic type. The Joinpoint Program uses permutation tests
to find a best fit of regression model with the smallest
number of “joinpoints” which are distinct linear segments
that differ statistically in their slopes. In addition, the
program can be used to test if trends between two
cohorts are statistically different (i.e., nonparallel) from
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each other. We obtained annual percentage change and
average annual percentage changes (AAPCs) from a log-
linear model in the joinpoint analysis using the logarithm
of observed rates. In addition, we also performed a linear
regression model using the observed rates to compute an
absolute change in the rate per year by race and histologic
type. Together, joinpoint analysis provided additional
information on race differences based on absolute and
relative changes in the incidence rate by histologic sub-
type. We also performed joinpoint analyses stratifying by
histology and tumor size.
Results
Among the 84,255 RCC patients, 48% of the tumors were
clear cell, 37% were NOS, 10% were papillary, and 5%
were chromophobe (Table 1). Excluding the NOS cases,
77% of the tumors were clear cell, 16% were papillary,
and 7% were chromophobe. The proportion of RCC cases
of clear cell histology among whites was higher than for
blacks (50% vs. 31% respectively), whereas black cases
were more likely than white cases to have papillary RCC
(23% vs. 9% respectively). Whites and blacks had similar
proportions of NOS cases (37% and 41%, respectively)
over the study period. Compared to whites, black patients
were four times as likely to have papillary RCC and twice
as likely to have chromophobe RCC than clear cell RCC
(Table 1). Asian or Pacific islanders were less likely to
have papillary or chromophobe type than clear cell as
compared with white patients (Table 1).
We observed an increasing trend (2001–2009) of
annual age-adjusted incidence rates for all three histologic
types, consistent with the increasing incidence overall, but
striking differences between whites and blacks in propor-
tionate incidence of the different subtypes (Fig. 1). For
clear cell type, both groups had a twofold increase in rates
from 2001 to 2009, increasing from 3.7 to 7.5 cases per
100,000 men and women for white patients and 2.7 to
5.4 for black patients.
In 2001, the beginning of the study period, blacks were
roughly two times more likely to have the papillary type
than whites. However, over the study period, the rise in
incidence of papillary was substantially larger for black
than for white patients (increasing from 1.6 to 4.0 for
black patients vs. 0.7 to 1.3 for white; P < 0.01). By 2009,
the incidence rate of papillary (4.0) approached that of
clear cell (5.4) in blacks. The chromophobe subtype was
more rarely diagnosed and the racial difference was no
longer statistically significant in 2009.
For the trends analysis, we found that that whites and
blacks had similar AAPC for clear cell, 9.6 and 9.8,
respectively (data not shown). For papillary, whites had
Table 1. Case–case comparisons of age, sex, and race distributions across renal cell carcinoma histologic subtypes.1
Descriptive data by subtype
N (%) OR (95% CI)
Clear cell (code 8310) NOS (code 8312) Papillary Chromophobe Papillary versus clear cell
Chromophobe
versus clear cell
Total 40,587 (48) 31,331 (37) 8518 (10) 3819 (5)
Age
<45 3778 (53) 2151 (30) 670 (9) 595 (8) 1 1
45–54 8031 (53) 4733 (31) 1488 (10) 778 (5) 1.05 (0.95–1.15) 0.62 (0.55–0.69)
55–64 11,526 (52) 7371 (33) 2547 (11) 922 (4) 1.25 (1.14–1.37) 0.51 (0.46–0.57)
65–74 10,311 (49) 7762 (37) 2313 (11) 851 (4) 1.27 (1.15–1.39) 0.52 (0.47–0.59)
75+ 6941 (38) 9314 (51) 1500 (8) 673 (4) 1.22 (1.10–1.35) 0.62 (0.55–0.69)
Per 10-year increase of age (continuous
variable)
1.05 (1.03–1.07) 0.90 (0.87–0.92)
Sex
Male 24,902 (47) 19,351 (36) 6591 (12) 2177 (4) 1 1
Female 15,685 (50) 11,980 (38) 1927 (6) 1642 (5) 0.46 (0.44–0.49) 1.20 (1.12–1.28)
Race
White 34,905 (50) 26,065 (37) 6168 (9) 3105 (4) 1 1
Black 2834 (31) 3796 (41) 2077 (23) 505 (5) 4.15 (3.90–4.42) 2.00 (1.81–2.22)
Asian/pacific islander 2147 (61) 1016 (29) 191 (5) 152 (4) 0.50 (0.43–0.59) 0.80 (0.67–0.94)
Other 701 (54) 454 (35) 82 (6) 57 (4) 0.66 (0.53–0.83) 0.91 (0.70–1.20)
1The following ICD-O-3 codes were used to identify these subtypes: 8310 or 8312 for clear cell, 8260 for papillary, 8317 and 8270 for chromo-
phobe. Data source is the SEER 18 registries database from November 2011 submission.
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an AAPC of 9.5, smaller than the AAPC of 12.1 for
blacks. These trends in subtype by race were considered
parallel in the joinpoint analysis. However, the slopes
based on observed incidence rates differed, with blacks
having a greater increase in slope than whites (0.09; 95%
CI = 0.08, 0.1 for whites and 0.30; 95% CI = 0.26, 0.34
for blacks). Moreover, among papillary tumors, blacks
experienced a greater increase in larger, clinically mean-
ingful tumors of 2–4 cm and >4 cm than among whites
over the study period (0.04 vs. 0.12, P = 0.026; and 0.04
vs. 0.14, P = 0.006).
Discussion
Using national data, we observed a higher proportion of
black RCC cases with papillary histology compared to
white cases, consistent with prior studies [30, 32], includ-
ing a prior SEER analysis [32] and an analysis of two
large international case–control studies with a common
central histopathologic review [26]. We also observed that
the well-documented rise in RCC rates in recent years
reflects an increase in all of the histologies of RCC. How-
ever, we also observed dynamic black–white incidence
differences in histologic RCC subtypes, and these changes
in rates are not equivalent. Rather, we are observing a lar-
ger increase in the disproportionate share of black cases
with papillary histology, with a widening of the gap
between blacks and whites in the incidence of this sub-
type.
Papillary RCC is the subtype about which perhaps the
least is known on the molecular level. Familial cases have
been linked to mutations in the cMET proto-oncogene
[37], and mutations in the fumarate hydratase gene, a key
enzyme in metabolism [38]. In contrast to clear cell RCC,
where VHL inactivation appears to be a canonical feature
in both hereditary and sporadic cases, mutations in these
genes are occasionally observed, but not recognized as
high-frequency events in sporadic papillary RCC. Further
work by the Cancer Genome Atlas consortium and other
integrated genomics efforts will shed light on the com-
mon genetic and molecular features of this tumor type. It
will be essential that cases of African descent are well rep-
resented in these cohorts. The identification of commonly
mutated genes or other molecular events will provide key
insights into the biology of this cancer, and in particular
any features differentiating white and black patients.
Established risk factors for RCC include cigarette smok-
ing, obesity, and hypertension; some of these associations
may vary by race or histologic subtype, as has been sug-
gested in recent studies [23, 26] While these risk factors
have not specifically been associated with papillary RCC
risk, there have not been any studies adequately powered
to examine the associations separately by race and histol-
ogy. Given the higher rates of tobacco exposure, obesity,
and hypertension among blacks, it may be reasonable to
explore the contribution that these risk factors may have
on the disproportionate rise in papillary RCC in black
cases. It will be important to consider genetic as well as
other epidemiologic factors in determining potential
mechanisms for the observed dynamic, subtype-specific
incidence trends we observed. The increased use of
abdominal imaging is also frequently invoked as an
explanatory hypothesis for the rise RCC incidence, to the
extent it leads to an increase in the incidental detection
of renal masses. Changing socioeconomic status and
improving access to healthcare services among blacks is
an important factor to consider, but may not explain a
decade long, race-specific increase in the detection of the
relatively rare papillary tumor type. Our findings high-
light several important population-wide features of this
cancer: (1) all subtypes are on the rise, and, (2) papillary
RCC, more common among black American patients, is
becoming more racially disparate. Our study strengths
include the use of a large dataset with standardized and
systematic ascertainment and classification of RCC cancer
cases. This resource permitted the estimation of nationally
representative incidence rates. In addition, a standard set
of demographic variables were also available. However,
lifestyle, environmental, and medical conditions are not
included in the SEER data and were not available for this
analysis.
The clinical significance of the observed larger and dis-
proportionately rising share of papillary cases among
blacks warrants further consideration, especially given the
Figure 1. Age-adjusted renal cell carcinoma by race and histologic
subtypes in 2001–2009, by black and white race. Incidence rates
shown on log scale. RCC NOS (ICD-O-3 8312) cases excluded. RCC,
renal cell carcinoma; NOS, not otherwise specified; ICD, international
classification of diseases.
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evidence that papillary and chromophobe RCC are associ-
ated with a better prognosis than clear cell RCC. Because
of evidence that most of the increases in RCC incidence
in recent decades have been in small (<4 cm, stage T1a)
and very small (<2 cm) localized renal masses, we
examined the size distribution of papillary cases, by race.
Among T1a cases, the proportion of <2 cm and 2–4 cm
masses was higher among whites versus blacks (14.4% vs.
11.9% and 38.8% vs. 34.2%, respectively), whereas the pro-
portion of masses >4 cm was higher in blacks (46/8% vs.
53.8%, respectively). Furthermore, the slope of increased
incidence in these groups in the joinpoint analysis was not
significantly different between the groups in the <2 cm stra-
tum, whereas the slope of increased incidence of 2–4 cm
and >4 cm tumors was significantly higher among blacks
over the study period (0.04 vs. 0.12 [P = 0.026] and 0.04 vs.
0.14 [P = 0.006], respectively). These data suggest that the
observed increased incidence of papillary histology among
blacks is not limited to the smallest, potentially clinically
insignificant size strata.
Additionally, although a standard pathologic review
protocol is employed across the study areas some uncer-
tainty in histologic classification remains. A large propor-
tion of cases were classified as ICD-O-3 code 8312 (RCC
NOS). In our original dataset code 8312 comprised
31,331 (37%) of RCC patients. A recent study of the
SEER-assigned histology compared to classification by an
independent pathologist found that the majority of cases
with the SEER-assigned ICD-O-3 code 8312 (RCC, NOS)
were classifiable as clear cell [34]. We conducted a sensi-
tivity analysis by comparing the age-adjusted rate of the
clear cell subtype using code 8312 alone and then com-
bining 8312 with clear cell (8310) (data not shown). The
results for our sensitivity analysis of the combined (ICD-
O-3 8310 and 8312) group are generally similar to those
for 8312 alone, including an elevated odds ratio for papil-
lary among blacks (data not shown). It appears that black
patients are also more likely to be diagnosed with ambig-
uous histopathologic codes. Further investigation of these
classification practices that may impact classification
among this subtype is warranted.
Novel targeted therapeutics are rapidly being generated
for RCC, including new treatments being tested for use in
subtype-specific scenarios, such as MET inhibitors for use
in papillary RCC. These findings highlight the growing
need to develop targeted therapies in order to address
issues of disparity in health care. More specifically, it
demonstrates the importance of developing better meth-
ods of detection or prevention of papillary RCC among
black Americans to be developed, and for improved
methods of subtype determination to be put forward,
potentially including molecular classification schemes, to
ensure that patients receive optimal care. Future epidemi-
ological, clinical, and genetic studies are needed to
advance the understanding of RCC subtypes such that a
clearer appreciation of the tumor subtype profile may pro-
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